HPMA copolymer-antibody-doxorubicin

Jelinkova M, Strohalm J, Etrych T, Ulbrich K, Rihova B. Starlike vs. classic macromolecular prodrugs Two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm Res 2003 20 1558-1564. 

Rihova B, Jelinkova M, Strohalm J, St astny M, Hovorka O, Plocova D, Kovar M, Draberova L, Ulbrich K. Antiproliferative effects of a lectin and anti-thy-1.2 antibody targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with mouse thy-1.2 gene. Bioconj Chem 2000 11 664-673. 

Jelinkova, M., Strohalm, J., Plocova, D., et al. Targeting of human and mouse T-lym-phocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J. Cont. Rel. 52 253-270, 1998. 

Fig. 14 A Polymer directed enzyme prodrug therapy (PDEPT) is a two-step approach that relies on activation of a polymer-drug conjugate by a complementary polymer-enzyme conjugate B PKl activated HPMA copolymer-Gly-Gly-cathepsin B C HPMA copolymer-Gly-Gly-cephalosporin-doxorubicin activated by HPMA copolymer-Gly-Gly-/3-lactamase D Etoposide prodrug (candidate for polymer conjugation) activated by HPMA copolymer-catalytic antibody 38C2...

---